Oncology Programs

Need Information?



DK049 is a novel derivative of the chemotherapeutic agent gemcitabine combined with a dual releasing linker. Preclinical data in animal models of pancreatic, ovarian and non-small cell lung cancers show superior anti-tumor effects compared to gemcitabine while using approximately one-sixth of the dose.

View 2016 AACR Annual Meeting DK049 Poster (PDF)